Abstract
Monoamine oxidase (MAO, E.C. 1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines. While MAO-A inhibitors are effective as antidepressant and anxiolytic drugs (e.g. chlorgyline, moclobemide, and lazabemide), inhibitors of MAO-B (e.g. Ldeprenyl, pargyline, and rasagiline) are used against neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Considering the need for novel MAO inhibitors due to side effects of the current ones, natural products have become attractive targets for researchers. Up till now, many studies revealed strong MAO inhibitory activity of flavonoid, xanthone, alkaloid, and coumarin derivatives from herbal sources, which also become good models for the synthetic MAO inhibitors. For this purpose, the present review focuses on examples of in vitro and in vivo MAO-inhibiting natural compounds of plant origin from a wide variety of chemical classes isolated mainly between 2000 – 2015.
Keywords: Monoamine oxidase, enzyme inhibition, natural compounds, MAO, flavonoid, alkaloid, coumarin.
Current Pharmaceutical Design
Title:Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors
Volume: 22 Issue: 3
Author(s): Ilkay Erdogan Orhan
Affiliation:
Keywords: Monoamine oxidase, enzyme inhibition, natural compounds, MAO, flavonoid, alkaloid, coumarin.
Abstract: Monoamine oxidase (MAO, E.C. 1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines. While MAO-A inhibitors are effective as antidepressant and anxiolytic drugs (e.g. chlorgyline, moclobemide, and lazabemide), inhibitors of MAO-B (e.g. Ldeprenyl, pargyline, and rasagiline) are used against neurodegenerative diseases such as Parkinson’s and Alzheimer’s diseases. Considering the need for novel MAO inhibitors due to side effects of the current ones, natural products have become attractive targets for researchers. Up till now, many studies revealed strong MAO inhibitory activity of flavonoid, xanthone, alkaloid, and coumarin derivatives from herbal sources, which also become good models for the synthetic MAO inhibitors. For this purpose, the present review focuses on examples of in vitro and in vivo MAO-inhibiting natural compounds of plant origin from a wide variety of chemical classes isolated mainly between 2000 – 2015.
Export Options
About this article
Cite this article as:
Orhan Erdogan Ilkay, Potential of Natural Products of Herbal Origin as Monoamine Oxidase Inhibitors, Current Pharmaceutical Design 2016; 22 (3) . https://dx.doi.org/10.2174/1381612822666151112150612
DOI https://dx.doi.org/10.2174/1381612822666151112150612 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prevalence of Cardiovascular and Metabolic Events in Patients Prescribed Clozapine: A Retrospective Observational, Clinical Cohort Study
Current Drug Safety Myopericarditis, as the First Sign of Rheumatoid Arthritis Relapse, Evaluated by Cardiac Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Concomitant Diagnosis of Fibromyalgia and Ankylosing Spondylitis: Relation to Clinical Features and Plasma Pentraxin -3 Level
Current Rheumatology Reviews Preface- Novel Targets for CNS Anti-Inflammatory Drug Development Interfering with Eicosanoid Formation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Prophylaxis with Bacopa monnieri Attenuates Acrylamide Induced Neurotoxicity and Oxidative Damage via Elevated Antioxidant Function
Central Nervous System Agents in Medicinal Chemistry Comparison of Extracellular and Intracellular Blood Compartments Highlights Redox Alterations in Alzheimer's and Mild Cognitive Impairment Patients
Current Alzheimer Research Biomarker Research of Preclinical Alzheimer’s Disease and MCI Based on Neuroimage Techniques
Neuroscience and Biomedical Engineering (Discontinued) Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin
CNS & Neurological Disorders - Drug Targets Peroxisome Proliferator-Activated Receptor (PPAR) in Metabolic Syndrome and Type 2 Diabetes Mellitus
Current Diabetes Reviews Jumping on the Train of Personalized Medicine: A Primer for Non- Geneticist Clinicians: Part 1. Fundamental Concepts in Molecular Genetics
Current Psychiatry Reviews Interplay Between ACE2 and Angiotensin-(1-7) in the Regulation of Blood Pressure
Current Hypertension Reviews Evidence that Pregnancy Specific Glycoproteins Regulate T-Cell Function and Inflammatory Autoimmune Disease During Pregnancy
Current Drug Targets - Inflammation & Allergy Plasma-Rich in Growth Factor and its Clinical Application
Current Stem Cell Research & Therapy Innate Immunity and Primary Biliary Cirrhosis
Current Molecular Medicine MMP-9, a Potential Target for Cerebral Ischemic Treatment
Current Neuropharmacology HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Approaches for the Development of Drugs for Treatment of Obesity and Metabolic Syndrome
Current Pharmaceutical Design The Safety of Medications for the Treatment of Bipolar Disorder During Pregnancy and the Puerperium
Current Drug Safety Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Parkinson's Disease: A Role for the Immune System
Current Molecular Pharmacology